

Richter divests its wholesale and retail operations in Romania

Budapest, Hungary – Prague, Czech Republic – 21 October 2022 – Gedeon Richter Plc. (“Richter”) and Dr. Max BDC, s.r.o. (“Dr.Max Group”) today announced that Richter’s indirect Romanian subsidiary, Armedica Trading S.R.L has signed a share sale and purchase agreement to divest the Richter Group’s Romanian wholesale and retail operations (Pharmafarm S.A. and Gedeon Richter Farmacia S.A., respectively) to Mediplus Exim S.R.L (“Mediplus”), a Romanian subsidiary of A&D Pharma, both being members of Dr.Max Group. The purchase price is due on the closure of the transaction pending on the approval of the Romanian competition authority.

“This agreement follows the divestiture of similar non-core businesses in the Republic of Moldova last year and it further increases strategic focus on core activities. The sustained protection of high margins achieved by our highly specialised pharmaceutical business segment is of paramount importance to Richter management,” – said Mr Gábor Orbán, CEO of Richter.

“The acquisition of Richter Group’s pharmaceutical retail and wholesale operations in Romania marks another big step in the expansion of Dr.Max Group on the Romanian Market and further solidifies our position among the Europe’s leading pharmacy chains,” – declared Leonardo Ferrandino, Dr.Max Group CEO.

“Thanks to this transaction, we will strengthen our position on retail as well as wholesale market. Due to a very limited overlap with our retail chain, the contemplated acquisition will allow us to cover a few white spots within our grid and provide more convenient services and wide product portfolio to our patients at locations we are already present. Hence, the transaction perfectly fits into our strategy,” – adds Cezar Zaharia, CEO of A&D Pharma.

About Richter

Gedeon Richter Plc. (www.gedeonrichter.com), headquartered in Budapest/Hungary, is a major pharmaceutical company in Central Eastern Europe, with an expanding direct presence in Western Europe, in China, in Latin America and in Australia. Having reached a market capitalization of EUR 4.4 billion (USD 5.0 billion) by the end of 2021, Richter’s consolidated sales were approximately EUR 1.8 billion (USD 2.1 billion) during the same year. The product portfolio of Richter covers many important therapeutic areas, including Women’s Healthcare, Central Nervous System and Cardiovascular areas. Having the largest R&D unit in Central Eastern Europe, Richter’s original research activity focuses on CNS disorders. With its widely acknowledged steroid chemistry expertise, Richter is a significant player in the Women’s Healthcare field worldwide. Richter is also active in biosimilar product development.

About Dr.Max Group and A&D Pharma

A&D Pharma

With over 25 years of experience on the local market, A&D Pharma (www.adpharma.com) – part of Dr.Max Group - is one of the largest and most dynamic pharmaceutical groups of companies in Romania, offering integrated services of import, distribution and retail of pharmaceutical products. With over 5,000 employees and a consolidated turnover of over EUR 1.2 billion, the group is present in the retail segment with over 760 pharmacies under the Dr.Max and Sensiblu brands, while also being one of the top players in import and distribution activities, servicing over 3,000 pharmacies through Mediplus.

Dr.Max Group

Dr.Max Group (www.drmax.eu) is with more than EUR 3 billion turnover, 2,300 pharmacies, 16,000 employees and 8 million loyal customers in the Czech Republic, Slovakia, Poland, Serbia, Romania and Italy, the largest omnichannel pharmacy chain in the CEE and the 3rd largest player in Europe. Its mission is to provide the patients with quality and affordable health care at reasonable prices.

Dr.Max can leverage on dedicated and professional employees, large and successful portfolio of own private label, modern supply chain or rapidly growing online business.

Moreover, Dr.Max Group owns a fast-growing marketing and sales business called MagnaPharm. It provides access to market together with marketing and promotional services to pharma producers. MagnaPharm is the 2nd largest player in the CEE region currently active in 17 countries.

For more information:

Richter:

Investors:

Katalin Ördög: +36 1 431 5680

Media:

Zsuzsa Beke: +36 1 431 4888

Dr.Max Group

Ivo Šenkyřík ivo.senkyrik@drmax.eu

A&D Pharma

Gabriel Ianculescu gabriel.ianculescu@adpharma.com